| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Shannon M Hough | |
| Erika M Price | |||
| Kimberly A Redic | |||
| P2860 | cites work | Clinical use of proteasome inhibitors in the treatment of multiple myeloma | Q28080999 |
| Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma | Q83358859 | ||
| Histone deacetylases and cancer | Q28240447 | ||
| Structure and mechanism of the Hsp90 molecular chaperone machinery | Q29615146 | ||
| Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. | Q33405714 | ||
| PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma | Q33409825 | ||
| Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. | Q33410225 | ||
| Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial | Q33417762 | ||
| Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma | Q33854012 | ||
| Controlling the double helix | Q34172152 | ||
| New insights into the treatment of multiple myeloma with histone deacetylase inhibitors | Q34224278 | ||
| Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. | Q34340318 | ||
| Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor | Q35070323 | ||
| The proteasome: structure, function, and role in the cell | Q35124091 | ||
| Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma | Q35571044 | ||
| Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. | Q36660672 | ||
| Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma | Q37753391 | ||
| Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma | Q37954600 | ||
| Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy | Q38115884 | ||
| Current strategies for treatment of relapsed/refractory multiple myeloma | Q38182683 | ||
| Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease | Q38360962 | ||
| Panobinostat: first global approval | Q38403118 | ||
| The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies | Q39596244 | ||
| In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma | Q39768627 | ||
| Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma | Q40070617 | ||
| Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells | Q42156460 | ||
| The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. | Q42163084 | ||
| Molecular sequelae of histone deacetylase inhibition in human malignant B cells | Q44280918 | ||
| Clinical course of patients with relapsed multiple myeloma | Q44544763 | ||
| Disease-specific survival for patients with multiple myeloma: significant improvements over time in all age groups | Q48084283 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2783-93 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | OncoTargets and Therapy | Q7092081 |
| P1476 | title | Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor | |
| P478 | volume | 9 |
Search more.